LMPG: Practice Guidelines And Recommendations For Use Of Tumor Markers In The Clinic
 (Draft Guidelines - Second Posting)

Table of Contents - Word Document Format
(Right click link to save file to your computer)

Section 1: Foreword and introduction (53 kb)

Section 2: Quality Requirements: Includes a summary of recommendations of the different sub-committees. (148 kb)

Section 3
3A: Use of Tumor Markers in Testicular Cancer (375 kb)

3B: Use of Tumor Markers in Prostate Cancer (201 kb)

3C: Use of Tumor Markers in Colorectal Cancer (142 kb)

3D: Use of Tumor Markers in Primary Liver Cancer (288 kb)

3E: Use of Tumor Markers in Ovarian Cancer (342 kb)

3F: Use of Tumor Markers in Breast Cancer (207 kb)

3G: Use of Tumor Markers in Gastric Cancer (70 kb)

3H: Use of Tumor Markers in Bladder Cancer (95 kb)

3I: Tumor Markers in Pancreatic Ductal Adenocarcinoma (677 kb)

3J: Use of Tumor Markers in Cervical Cancer (97 kb)

3K: Use of Tumor Markers in Monoclonal Gammopathies (128 kb)

3L: Use of Tumor Markers in Malignant Melanoma (211 kb)

3M: Use of Tumor Markers in Parathyroid Gland Adenomas and Carcinomas (124 kb)

3N: Use of Tumor Markers in Neoplasms of the Dispersed Neuroendocrine System (104 kb)

3O: Use of Tumor Markers in Differentiated Epithelial Thyroid Carcinoma (101 kb)

3P: Use of Tumor Markers in Lung Cancer (172 kb)

Section 4

4A: Use of Microarrays in Cancer Diagnostics (69 kb)

4B: Use of MALDI-TOF Mass Spectometry Profiling to Diagnose Cancer (351 kb)